Accuracy of an Automated Plasma Apolipoprotein E4 Proteotyping Immunoassay for Determination of APOE Genotype

Abstract

Background: Anti‐amyloid therapies (AAT) for Alzheimer's disease are associated with the risk of amyloid‐related imaging abnormalities (ARIA). APOE4 homozygotes (E4/E4) have the highest risk, followed by APOE4 carriers (E4), making APOE genotyping essential for risk assessment.

The paper